ASCO preview: Merck's Keytruda, Novartis' Kisqali face their moment of truth in...

cafead

Administrator
Staff member
  • cafead   May 25, 2023 at 08:42: PM
via Two cancers studies are slated to grab significant attention at the upcoming American Society of Clinical Oncology 2023 annual meeting, and each could lead to a major label expansion for the companies involved.

article source